BR112014028600A2 - formulações de anticorpo monoclonal de alta concentração - Google Patents
formulações de anticorpo monoclonal de alta concentraçãoInfo
- Publication number
- BR112014028600A2 BR112014028600A2 BR112014028600A BR112014028600A BR112014028600A2 BR 112014028600 A2 BR112014028600 A2 BR 112014028600A2 BR 112014028600 A BR112014028600 A BR 112014028600A BR 112014028600 A BR112014028600 A BR 112014028600A BR 112014028600 A2 BR112014028600 A2 BR 112014028600A2
- Authority
- BR
- Brazil
- Prior art keywords
- monoclonal antibody
- high concentration
- antibody formulations
- concentration monoclonal
- formulations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261649146P | 2012-05-18 | 2012-05-18 | |
US61/649,146 | 2012-05-18 | ||
PCT/US2013/041532 WO2013173687A1 (en) | 2012-05-18 | 2013-05-17 | High-concentration monoclonal antibody formulations |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112014028600A2 true BR112014028600A2 (pt) | 2017-08-01 |
BR112014028600A8 BR112014028600A8 (pt) | 2021-09-14 |
BR112014028600B1 BR112014028600B1 (pt) | 2022-11-22 |
Family
ID=48471141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014028600-0A BR112014028600B1 (pt) | 2012-05-18 | 2013-05-17 | Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação |
Country Status (22)
Country | Link |
---|---|
US (3) | US20130309226A1 (pt) |
EP (2) | EP3427721A1 (pt) |
JP (3) | JP6254581B2 (pt) |
KR (2) | KR102201607B1 (pt) |
CN (2) | CN108187043A (pt) |
AU (3) | AU2013262611B2 (pt) |
BR (1) | BR112014028600B1 (pt) |
CA (1) | CA2873646C (pt) |
ES (1) | ES2682761T3 (pt) |
HK (2) | HK1207826A1 (pt) |
HR (1) | HRP20181211T1 (pt) |
IL (3) | IL235716B (pt) |
MX (1) | MX355611B (pt) |
MY (1) | MY188825A (pt) |
NZ (3) | NZ701915A (pt) |
PL (1) | PL2849723T3 (pt) |
RU (2) | RU2711089C2 (pt) |
SG (2) | SG11201407512VA (pt) |
SI (1) | SI2849723T1 (pt) |
TR (1) | TR201810930T4 (pt) |
WO (1) | WO2013173687A1 (pt) |
ZA (2) | ZA201408651B (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013023062B1 (pt) | 2011-03-10 | 2022-01-18 | Xeris Pharmaceuticals, Inc | Solução estável para a injeção parenteral e método de fabricação da mesma |
KR20220063293A (ko) | 2011-11-18 | 2022-05-17 | 리제너론 파마슈티칼스 인코포레이티드 | 폴리머 단백질 미립자 |
US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
AU2014295052B2 (en) | 2013-07-23 | 2018-08-30 | Novaliq Gmbh | Stabilized antibody compositions |
US9925263B2 (en) | 2013-09-11 | 2018-03-27 | Eagle Biologics, Inc. | Liquid pharmaceutical formulations for injection comprising procaine and uses thereof |
US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
JP6738316B2 (ja) * | 2014-07-17 | 2020-08-12 | ノヴォ ノルディスク アクティーゼルスカブ | 粘度を低下させるためのtrem−1抗体の部位特異的変異誘発 |
EP3871709A1 (en) * | 2014-08-06 | 2021-09-01 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
KR102497368B1 (ko) | 2014-10-01 | 2023-02-10 | 이글 바이올로직스 인코포레이티드 | 점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형 |
WO2016120753A1 (en) | 2015-01-28 | 2016-08-04 | Pfizer Inc. | Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
US20170056504A1 (en) * | 2015-09-02 | 2017-03-02 | Kenneth I. Kohn | Method of extending half-life of crystaline antibodies |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
HUE060148T2 (hu) | 2015-12-16 | 2023-02-28 | Regeneron Pharma | Fehérje mikroszemcsékbõl álló készítmények és gyártási módszereik |
CA3019482A1 (en) | 2016-03-31 | 2017-10-05 | Vhsquared Limited | Compositions |
MA46466A (fr) | 2016-10-06 | 2019-08-14 | Amgen Inc | Formulations pharmaceutiques de protéines à viscosité réduite |
WO2018078186A1 (en) | 2016-10-31 | 2018-05-03 | Vectura Limited | Inhalable powder composition comprising il-13 antibody |
US10646569B2 (en) | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
AU2018275686B2 (en) | 2017-06-02 | 2024-02-01 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
CN113164618A (zh) | 2018-09-12 | 2021-07-23 | 希沃尔拜克治疗公司 | 用免疫刺激性缀合物治疗疾病的方法和组合物 |
WO2020071876A1 (ko) * | 2018-10-04 | 2020-04-09 | 삼성바이오에피스 주식회사 | 점도가 감소된 고농도 트라스투주맙 또는 이의 항원 결합 단편 안정화 제제 |
SG11202104166QA (en) * | 2018-11-21 | 2021-05-28 | Regeneron Pharma | High concentration protein formulation |
SG11202107901QA (en) | 2019-02-05 | 2021-08-30 | Lindy Biosciences Inc | Isolated cell culture components and methods for isolating the same from liquid cell culture medium |
US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
BR112021017536A2 (pt) * | 2019-03-06 | 2021-11-09 | Zoetis Services Llc | Composições de suspensão injetáveis prontas para uso e uso das mesmas para tratar uma infecção bacteriana em um animal |
SG11202110546UA (en) * | 2019-04-11 | 2021-10-28 | R P Scherer Technologies Llc | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability |
US11684655B2 (en) | 2019-05-31 | 2023-06-27 | Spectrum Pharmaceuticals, Inc. | Methods of treating neutorpenia using G-CSF protein complex |
WO2020257407A1 (en) | 2019-06-19 | 2020-12-24 | Silverback Therapeutics, Inc. | Anti-mesothelin antibodies and immunoconjugates thereof |
US20230056445A1 (en) | 2019-06-21 | 2023-02-23 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
US20220242945A1 (en) | 2019-06-21 | 2022-08-04 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
WO2021105392A1 (en) * | 2019-11-27 | 2021-06-03 | Novaliq Gmbh | Suspension comprising a protein particle suspended in a non-aqueous vehicle |
CN113082203B (zh) * | 2020-01-09 | 2023-10-20 | 鲁南制药集团股份有限公司 | 一种免疫抑制剂单克隆抗体的液体制剂 |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
EP4175673A1 (en) | 2020-07-01 | 2023-05-10 | ARS Pharmaceuticals Inc. | Anti-asgr1 antibody conjugates and uses thereof |
KR102375269B1 (ko) * | 2021-01-27 | 2022-03-17 | 한미약품 주식회사 | 단백질 액상 제제 및 이의 제조방법 |
JP2024514896A (ja) | 2021-08-05 | 2024-04-03 | エルジー エナジー ソリューション リミテッド | 電極組立体、円筒形バッテリーセル、及びこれを含むバッテリーパック及び自動車 |
JP2024516737A (ja) | 2021-08-05 | 2024-04-16 | エルジー エナジー ソリューション リミテッド | 電極組立体、バッテリー、それを含むバッテリーパック及び自動車 |
IL311336A (en) * | 2021-09-09 | 2024-05-01 | Xeris Pharmaceuticals Inc | High-concentration injectable pharmaceutical formulations and methods of production and use thereof |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE947335C (de) | 1954-10-19 | 1956-08-16 | Schering Ag | Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron |
GB1225979A (pt) | 1967-03-23 | 1971-03-24 | ||
US3639587A (en) | 1969-11-07 | 1972-02-01 | Eastman Kodak Co | Medicinal compositions for administration to animals and process for administering same |
US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
DE2949849A1 (de) | 1979-12-12 | 1981-06-19 | A. Nattermann & Cie GmbH, 5000 Köln | Phosphatidylcholin-loesungen |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
ATE113846T1 (de) | 1988-06-21 | 1994-11-15 | Genentech Inc | Therapeutische zusammensetzungen für die behandlung von myocard-infarkten. |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
CA2113813C (en) | 1991-08-14 | 2005-04-12 | Paula M. Jardieu | Immunoglobulin variants for specific fc epsilon receptors |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
CA2128862C (en) | 1992-02-11 | 2008-05-20 | Jonathan G. Seidman | Homogenotization of gene-targeting events |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
ZA936128B (en) | 1992-08-21 | 1995-02-20 | Genentech Inc | Method for treating a LFA-1 mediated disorder |
CA2176811C (en) | 1993-12-10 | 2008-01-29 | David Tai Wai Fei | Methods for diagnosis of allergy and screening of anti-allergy therapeutics |
ATE164079T1 (de) | 1994-01-18 | 1998-04-15 | Genentech Inc | Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten |
US5707622A (en) | 1994-03-03 | 1998-01-13 | Genentech, Inc. | Methods for treating ulcerative colitis |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
EP1516628B1 (en) * | 1995-07-27 | 2013-08-21 | Genentech, Inc. | Stable isotonic lyophilized protein formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
DE69714966T2 (de) | 1996-01-23 | 2003-04-24 | Genentech Inc | Antikörper gegen cd 18 zur verwendung gegen gehirnschlag |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
KR100532178B1 (ko) | 1996-11-27 | 2005-12-01 | 제넨테크, 인크. | 인간화 항-CD11a 항체 |
DK1860187T3 (da) | 1997-05-15 | 2011-10-31 | Genentech Inc | Apo-2-receptor |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
JP2001521909A (ja) | 1997-10-31 | 2001-11-13 | ジェネンテク・インコーポレイテッド | 糖タンパク質グリコフォームを含む方法及び組成物 |
IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
US6284282B1 (en) | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
NZ518477A (en) | 1999-10-29 | 2004-10-29 | Genentech Inc | Isolated anti-prostate stem cell antigen (PSCA) antibodies that internalise upon binding to PSCA on a mammalian cell, including a PSCA-expressing tumour cell, in vivo |
ES2477996T3 (es) | 2000-08-11 | 2014-07-18 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen un anticuerpo |
EP1324776B2 (en) | 2000-10-12 | 2018-03-21 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
NZ581474A (en) | 2001-08-03 | 2011-04-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
WO2003068934A2 (en) | 2002-02-14 | 2003-08-21 | Rutter William J | Chimeric molecules for cleavage in a treated host |
CN100522999C (zh) | 2002-02-14 | 2009-08-05 | 免疫医疗公司 | 抗cd20抗体及其融合蛋白和使用方法 |
KR20040085185A (ko) | 2002-02-14 | 2004-10-07 | 추가이 세이야쿠 가부시키가이샤 | 항체함유 용액제제 |
AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
EP2316856B1 (en) | 2002-10-17 | 2017-08-09 | Genmab A/S | Human monoclonal antibodies against CD20 |
JP2006516408A (ja) | 2003-02-01 | 2006-07-06 | タノックス インコーポレーテッド | 高親和性抗体の生成方法 |
PL1610820T5 (pl) * | 2003-04-04 | 2014-01-31 | Genentech Inc | Preparaty zawierające wysokoskoncentrowane przeciwciała i białka |
WO2004105798A1 (en) | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α |
KR20160114727A (ko) * | 2003-05-30 | 2016-10-05 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
LT2348051T (lt) | 2003-11-05 | 2019-02-25 | Roche Glycart Ag | Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija |
EP1753404A1 (en) * | 2004-05-12 | 2007-02-21 | Baxter International Inc. | Microspheres comprising protein and showing injectability at high concentrations of said agent |
MX2007001760A (es) | 2004-08-12 | 2007-07-24 | Quest Pharmaceutical Services | Composiciones farmaceuticas para la distribucion de liberacion controlada de compuestos biologicamente activos. |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US20060141040A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
US20060216242A1 (en) | 2005-02-03 | 2006-09-28 | Rohloff Catherine M | Suspending vehicles and pharmaceutical suspensions for drug dosage forms |
CN101237857A (zh) * | 2005-05-09 | 2008-08-06 | 生物领域医疗公司 | 使用微球和非离子型造影剂的组合物和方法 |
US7390786B2 (en) * | 2005-12-21 | 2008-06-24 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
EP1977763A4 (en) * | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | STABILIZER PREPARATION CONTAINING ANTIBODIES |
AU2007212147A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
WO2008011348A2 (en) | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
US20090022727A1 (en) * | 2007-01-26 | 2009-01-22 | Alza Corp. | Injectable, nonaqueous suspension with high concentration of therapeutic agent |
PT2132230E (pt) | 2007-03-22 | 2014-07-17 | Genentech Inc | Anticorpos apoptóticos anti-ige que se ligam ao ige ligado a membrana |
US7611705B2 (en) * | 2007-06-15 | 2009-11-03 | National Cheng Kung University | Anti-IL-20 antibody and its use in treating IL-20 associated inflammatory diseases |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
CN104188911A (zh) | 2008-01-15 | 2014-12-10 | Abbvie德国有限责任两合公司 | 粉末状蛋白质组合物及其制备方法 |
EP2376522A4 (en) * | 2008-11-16 | 2013-12-25 | Univ Texas | LOW VISCOSIS HIGHLY CONCENTRATED SUSPENSIONS |
EP2367572B1 (en) * | 2008-11-19 | 2018-08-29 | Merial, Inc. | Formulations comprising ceftiofur and benzyl alcohol |
UA106070C2 (uk) | 2009-03-20 | 2014-07-25 | Дженентек, Інк. | Антитіло, що специфічно зв'язується з egfr і her3 |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
US10029013B2 (en) * | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
US20130202693A1 (en) * | 2010-06-02 | 2013-08-08 | Astellas Deutschland Gmbh | Oral Dosage Forms of Bendamustine |
-
2013
- 2013-05-17 CN CN201810150067.1A patent/CN108187043A/zh active Pending
- 2013-05-17 MX MX2014013868A patent/MX355611B/es active IP Right Grant
- 2013-05-17 MY MYPI2014003184A patent/MY188825A/en unknown
- 2013-05-17 CN CN201380037115.1A patent/CN104427974B/zh active Active
- 2013-05-17 JP JP2015512877A patent/JP6254581B2/ja active Active
- 2013-05-17 RU RU2014151359A patent/RU2711089C2/ru active
- 2013-05-17 WO PCT/US2013/041532 patent/WO2013173687A1/en active Application Filing
- 2013-05-17 CA CA2873646A patent/CA2873646C/en active Active
- 2013-05-17 KR KR1020147035067A patent/KR102201607B1/ko active IP Right Grant
- 2013-05-17 NZ NZ701915A patent/NZ701915A/en unknown
- 2013-05-17 SG SG11201407512VA patent/SG11201407512VA/en unknown
- 2013-05-17 PL PL13724493T patent/PL2849723T3/pl unknown
- 2013-05-17 US US13/896,622 patent/US20130309226A1/en not_active Abandoned
- 2013-05-17 SG SG10201709555SA patent/SG10201709555SA/en unknown
- 2013-05-17 EP EP18169218.7A patent/EP3427721A1/en active Pending
- 2013-05-17 AU AU2013262611A patent/AU2013262611B2/en active Active
- 2013-05-17 ES ES13724493.5T patent/ES2682761T3/es active Active
- 2013-05-17 BR BR112014028600-0A patent/BR112014028600B1/pt active IP Right Grant
- 2013-05-17 SI SI201331115T patent/SI2849723T1/sl unknown
- 2013-05-17 EP EP13724493.5A patent/EP2849723B1/en active Active
- 2013-05-17 TR TR2018/10930T patent/TR201810930T4/tr unknown
- 2013-05-17 KR KR1020207019704A patent/KR102326359B1/ko active IP Right Grant
- 2013-05-17 RU RU2019142698A patent/RU2019142698A/ru unknown
- 2013-05-17 NZ NZ737862A patent/NZ737862A/en unknown
- 2013-05-17 NZ NZ725654A patent/NZ725654A/en unknown
-
2014
- 2014-11-13 IL IL235716A patent/IL235716B/en active IP Right Grant
- 2014-11-25 ZA ZA2014/08651A patent/ZA201408651B/en unknown
-
2015
- 2015-06-26 US US14/752,670 patent/US20160176986A1/en not_active Abandoned
- 2015-09-01 HK HK15108509.0A patent/HK1207826A1/xx unknown
-
2017
- 2017-11-30 JP JP2017230012A patent/JP7015156B2/ja active Active
-
2018
- 2018-06-01 AU AU2018203876A patent/AU2018203876B2/en active Active
- 2018-07-26 HR HRP20181211TT patent/HRP20181211T1/hr unknown
- 2018-12-24 HK HK18116515.2A patent/HK1257554A1/zh unknown
-
2019
- 2019-04-12 US US16/383,270 patent/US20200087415A1/en not_active Abandoned
- 2019-07-25 IL IL268280A patent/IL268280B/en active IP Right Grant
- 2019-11-18 JP JP2019207949A patent/JP2020059716A/ja active Pending
-
2020
- 2020-07-09 AU AU2020204588A patent/AU2020204588A1/en not_active Abandoned
-
2021
- 2021-04-29 IL IL282805A patent/IL282805A/en unknown
- 2021-11-19 ZA ZA2021/09290A patent/ZA202109290B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014028600A2 (pt) | formulações de anticorpo monoclonal de alta concentração | |
FR23C1023I2 (fr) | Anticorps anti-il-36r | |
FR22C1018I2 (fr) | Anticorps egfr/c-met bispecifiques | |
LTC2579894I2 (lt) | CGRP antikūnai | |
DK2858671T3 (da) | Antistofformulering | |
DK2890397T3 (da) | Antiprolactinreceptor-antistofformulering | |
DK3117837T3 (da) | Antistofformuleringer | |
DK2934584T3 (da) | Anti-gdf15-antistoffer | |
IL240754A0 (en) | Low concentration antibody compositions | |
BR112013011699A2 (pt) | formulações líquidas de elevada concentração de anticorpo anti-tnfa melhoradas | |
DK2850101T3 (da) | Anti-FcRn-antistoffer | |
CO7071096A2 (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
CO6811812A2 (es) | Anticuerpo anti-b7-h3 | |
BR112015002193A2 (pt) | anticorpos anti-etbr e imunoconjugados | |
DK3049441T3 (da) | Anti-PDL1-antistofformuleringer | |
BR112014024769A2 (pt) | anticorpo humanizado tau | |
CO6801637A2 (es) | Formulaciones de anticuerpos | |
DK3156416T3 (da) | Sekvenssymmetriske modificerede bispecifikke igg4-antistoffer | |
DK2847231T3 (da) | Multispecifikke monoklonale antistoffer | |
BR112012030311A2 (pt) | anticorpo | |
CR20140127A (es) | Anticuerpo anti-abtcr | |
DK3381943T3 (da) | Anti-kit-antistoffer og anvendelser deraf | |
BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
EP2934587A4 (en) | LIQUID FORMULATIONS FOR ANTI-TNFALPHA ANTIBODY | |
CL2015001266A1 (es) | Anticuerpos de antihemaglutinina y métodos de uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/05/2013, OBSERVADAS AS CONDICOES LEGAIS |